Squarepoint
AVIR icon

Squarepoint’s Atea Pharmaceuticals AVIR Stock Holding History

Squarepoint’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-29,316
Closed -$136K – 4406
2026
Q2 		$136K Sell
29,316
-25,782
-47% -$128K ﹤0.01% 4147
2026
Q1 		$296K Buy
55,098
+35,787
+185% +$164K ﹤0.01% 3720
2025
Q4 		$68.9K Buy
+19,311
New +$61.4K ﹤0.01% 4097
2025
Q2 		– Sell
-15,756
Closed -$47.1K – 4476
2025
Q1 		$47.1K Sell
15,756
-34,994
-69% -$109K ﹤0.01% 4350
2024
Q4 		$170K Buy
50,750
+35,053
+223% +$116K ﹤0.01% 4533
2024
Q3 		$52.6K Buy
15,697
+1,057
+7% +$3.83K ﹤0.01% 3977
2024
Q2 		$48.5K Sell
14,640
-5,513
-27% -$20.6K ﹤0.01% 3908
2024
Q1 		$81.4K Buy
+20,153
New +$78.9K ﹤0.01% 3826
2023
Q4 		– Sell
-41,308
Closed -$124K – 3997
2023
Q3 		$124K Buy
41,308
+22,117
+115% +$75.3K ﹤0.01% 3529
2023
Q2 		$71.8K Sell
19,191
-3,586
-16% -$13.4K ﹤0.01% 3405
2023
Q1 		$76.3K Sell
22,777
-16,237
-42% -$65.9K ﹤0.01% 3016
2022
Q4 		$188K Buy
+39,014
New +$197K ﹤0.01% 2808
2022
Q1 		– Sell
-213,220
Closed -$1.91M – 2806
2021
Q4 		$1.91M Buy
+213,220
New +$3.32M 0.01% 1297

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Squarepoint's AVIR Position: Q3 2026 in Review

Squarepoint sold out of Atea Pharmaceuticals (AVIR) in Q3 2026, closing a stake of 29,316 shares — an estimated $136K sold.

Squarepoint first reported a position in AVIR in Q4 2021 and held it in 13 quarters. The position peaked at $1.91M in Q4 2021. 68 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Squarepoint reported no remaining Atea Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 29,316 Atea Pharmaceuticals shares in Q3 2026, an estimated $136K.
  • Squarepoint first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Squarepoint's Atea Pharmaceuticals position peaked at $1.91M in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.